Meitav Investment House Ltd. Has $15.16 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Meitav Investment House Ltd. boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 96.6% in the third quarter, Holdings Channel reports. The institutional investor owned 226,903 shares of the company’s stock after acquiring an additional 111,475 shares during the quarter. Meitav Investment House Ltd.’s holdings in Moderna were worth $15,164,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC acquired a new position in Moderna in the 2nd quarter worth about $26,000. Cedar Wealth Management LLC grew its stake in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares in the last quarter. Westside Investment Management Inc. acquired a new position in Moderna in the first quarter worth approximately $32,000. Family Firm Inc. bought a new position in Moderna during the second quarter valued at approximately $33,000. Finally, Bank & Trust Co bought a new position in Moderna during the second quarter valued at approximately $36,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 1.1 %

NASDAQ MRNA opened at $54.12 on Thursday. Moderna, Inc. has a twelve month low of $52.26 and a twelve month high of $170.47. The stock has a market cap of $20.74 billion, a PE ratio of -3.49 and a beta of 1.66. The firm has a 50-day simple moving average of $65.70 and a 200 day simple moving average of $101.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the firm posted ($3.62) EPS. The company’s revenue for the quarter was down 29.9% on a year-over-year basis. On average, research analysts forecast that Moderna, Inc. will post -9.88 EPS for the current year.

Insider Activity

In other news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,184 shares of company stock worth $238,531. Company insiders own 15.70% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the topic of several analyst reports. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and decreased their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Sanford C. Bernstein initiated coverage on shares of Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective for the company. Finally, Leerink Partners lowered their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $94.65.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.